information for patients and other non-professionals.
The information on this website is for general informational purposes only and does not constitute medical advice. Amalus Therapeutics' research is still in a preclinical phase and has not been tested in humans. Many steps are required before clinical trials can begin and a potential therapy can be approved. Please consult your doctor before making any decisions regarding your health or treatment.
Everyone regards the elimination of these 'corrupt' fibroblasts as promising, but 'normal' fibroblasts are also present in our body. They perform vital functions and are difficult to distinguish from their malicious counterparts. Amalus Therapeutics has found a way to selectively 'deradicalize' these 'corrupt' fibroblasts. All other fibroblast inhibitors also disrupt normal fibroblasts. They are not useful because they cause serious side effects and do not work sufficiently at lower doses. In animal models we see that our products are well tolerated, normalize the environment around the tumor, strongly inhibit metastases and activate the immune system.
We envisage that our products will be effective in themselves, but that they can also boost the effect of standard therapies in oncology. Such products are in high demand because they provide a better outcome for the patient, while doctors can build on a trusted treatment strategy.
Amalus Therapeutics is developing a new class of drugs that selectively target corrupt fibroblast cells. This innovative approach offers the potential to greatly improve the prospects of patients with cancer or fibrotic diseases.
Fibroblast cells play a central, negative role in difficult-to-treat cancers and fibrosis. In cancer, for example, they build a shield around the tumor and turn it into a fortress that is difficult to conquer. As a result, the immune system and current therapies cannot fight the tumor properly. Fibroblasts also support the tumor in other ways: they stimulate growth and metastasis, and reprogram the immune system so that it tolerates the tumor.
explanation using only the most common English words.
Talk to your doctor before making any decisions regarding your health or treatment.
Everyone thinks that getting rid of these 'bad' fibroblasts is good, but 'normal' fibroblasts are also in our body. They do important things and are hard to tell apart from their bad friends. Amalus Therapeutics has found a way to only 'make good' these 'bad' fibroblasts. All other fibroblast stoppers also mess up normal fibroblasts. They are not useful because they cause serious problems and do not work well at lower amounts. In animal tests we see that our products are easy to take, make the area around the tumor normal, stop spreading very well and turn on the body's defense system.
We think that our products will work by themselves, but that they can also make the effect of usual drugs in cancer better. Such products are wanted a lot because they make the result for the person better, while doctors can use a trusted way of treatment.
Amalus Therapeutics is making a new kind of drugs that only go after bad fibroblast cells. This new way of doing things could make the chances of people with cancer or fibrotic diseases much better.
Fibroblast cells have a big, bad role in hard-to-treat cancers and fibrosis. In cancer, for example, they make a wall around the tumor and make it into a strong place that is hard to beat. As a result, the body's defense system and current drugs cannot fight the tumor well. Fibroblasts also help the tumor in other ways: they make it grow and spread, and change the body's defense system so that it lets the tumor be.